Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Mir

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2022
Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1-CREB1 fusion and ALK overexpressionC Ngo, T Grinda, A Boilève, et al.
ESMO Open|December 5, 2021
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics studyL Cerbone, D Combarel, A Geraud, et al.
European Journal of Cancer (Oxford, England : 1990)|April 11, 2018
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumoursH Herin, S Aspeslagh, E Castanon, et al.
ESMO Open|December 11, 2024
Sex differences in the pharmacokinetics of anticancer drugs: a systematic reviewJ Delahousse, A D Wagner, S Borchmann, et al.
ESMO Open|December 9, 2022
Cytochrome P-450-mediated herb and food-drug interactions can be identified in cancer patients through patient self-reporting with a tablet application: results of a prospective observational studyP Gougis, A Géraud, M Hilmi, et al.
Surgical Oncology|June 15, 2019
Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patientsC Honoré, J B Delhorme, E Nassif, et al.
ESMO Open|March 7, 2022
Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trialsE F Nassif, J-Y Blay, C Massard, et al.
ESMO Open|February 1, 2021
Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomasM Brahmi, T Lesluyes, A Dufresne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2013
Advanced chondrosarcomas: role of chemotherapy and survivalA Italiano, O Mir, A Cioffi, et al.
Oncoimmunology|September 14, 2020
Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcomaA Dufresne, T Lesluyes, C Ménétrier-Caux, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2022
Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1-CREB1 fusion and ALK overexpressionC Ngo, T Grinda, A Boilève, et al.
ESMO Open|December 5, 2021
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics studyL Cerbone, D Combarel, A Geraud, et al.
European Journal of Cancer (Oxford, England : 1990)|April 11, 2018
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumoursH Herin, S Aspeslagh, E Castanon, et al.
ESMO Open|December 11, 2024
Sex differences in the pharmacokinetics of anticancer drugs: a systematic reviewJ Delahousse, A D Wagner, S Borchmann, et al.
ESMO Open|December 9, 2022
Cytochrome P-450-mediated herb and food-drug interactions can be identified in cancer patients through patient self-reporting with a tablet application: results of a prospective observational studyP Gougis, A Géraud, M Hilmi, et al.
Surgical Oncology|June 15, 2019
Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patientsC Honoré, J B Delhorme, E Nassif, et al.
ESMO Open|March 7, 2022
Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trialsE F Nassif, J-Y Blay, C Massard, et al.
ESMO Open|February 1, 2021
Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomasM Brahmi, T Lesluyes, A Dufresne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2013
Advanced chondrosarcomas: role of chemotherapy and survivalA Italiano, O Mir, A Cioffi, et al.
Oncoimmunology|September 14, 2020
Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcomaA Dufresne, T Lesluyes, C Ménétrier-Caux, et al.
Pageof 8